Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» HPN424
HPN424
Harpoon cuts bait with lead program after failing to find silver linings from ASCO data, other studies
Endpoints
Fri, 03/11/22 - 11:04 am
Harpoon Therapeutics
HPN424
prostate cancer
Harpoon Therapeutics Begins Trial of Novel Immuno-Oncololgy Drug in Patients with Metastatic Castration-Resistant Prostate Cancer
CP Wire
Mon, 08/6/18 - 09:46 am
Harpoon Therapeutics
HPN424
metastatic castration-resistant prostate cancer
Harpoon Therapeutics Begins Trial of Novel Immuno-Oncololgy Drug in Patients with Metastatic Castration-Resistant Prostate Cancer
Mon, 08/6/18 - 09:20 am
Harpoon Therapeutics
HPN424
metastatic castration-resistant prostate cancer